University of Oxford.
Oxford University Hospitals NHS Trust.
Blood. 2024 Nov 28;144(22):2278-2279. doi: 10.1182/blood.2024026811.
In this issue of Blood, Reis et al1 identify a monoclonal antibody, INCA033989, that selectively targets mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs), inhibiting its oncogenic activity without affecting normal hematopoiesis.
在本期《Blood》中, Reis 等人 1 鉴定出一种单克隆抗体 INCA033989,该抗体能选择性地靶向骨髓增殖性肿瘤(MPN)中的突变钙网织蛋白(mutCALR),抑制其致癌活性而不影响正常造血。